Skip to content

Study · Not a test of the peptide alone · 2000

1 result

Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS.

Tuthill CW, Rudolph A, Li Y, Tan B, Fitzgerald TJ, Beck SR, Li YX

AAPS PharmSciTech14 May 2000Cited by 13 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    An LC-MS/MS method for thymosin alpha‑1 in human serum had a lower quantitation limit of 0.5 ng/mL and a calibration range of 0.5 to 100 ng/mL.

    In plain wordsIn lab tests, a mass spectrometry method could measure thymosin alpha‑1 in human serum down to 0.5 ng/mL.

    Outcome
    Not applicableLC-MS/MS lower limit of quantitation in human serum
    Study

    n: not reported in source

    human serum
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Lower quantitation limit
    0.5 ng/mL
    human serum
    Calibration range
    0.5 to 100 ng/mL
    human serum

    Source sentences

    Summary
    The lower quantitation limit was 0.5 ng/mL Talpha1 in human serum. Calibration curves were established between 0.5 to 100 ng/mL by weighted linear regression.
    1 context sentence
    Summary · context
    A high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was developed to measure the thymosin alpha 1 (Talpha1) concentration in human serum.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.